Research and Development Department, Sahajanand Medical Technologies (SMT) Pvt. Ltd., Surat, India.
Colloids Surf B Biointerfaces. 2012 May 1;93:180-7. doi: 10.1016/j.colsurfb.2011.12.034. Epub 2012 Jan 8.
Understanding the in-vitro release profile of drugs from drug eluting devices such as cardiac stent is crucial in designing and optimizing the drug embedded matrices. Sirolimus (SRL), a widely used anti-inflammatory/antiproliferative/immunosuppressive hydrophobic drug undergoes irreversible changes such as hydrolysis leading to erroneous assessment of the release profile. The release profile mainly depends on the drug release medium. The present study aims to develop and optimize the aqueous medium for the solubilization of SRL and in-vitro release method from drug eluting stent (DES). In the first stage of study several release media containing different buffer compositions, pH, and a series of micelle forming PEO-PPO-PEO block copolymers (known as Pluronic(®)) were examined for solubility and stability of SRL by reversed phase high performance liquid chromatography (RP-HPLC). SRL showed good solubility and stability at pH 4.0 (both in acetate buffer as well in phosphate buffer) in the presence of block copolymers. Solubilization of SRL was remarkably higher in P103 and P123 micelles than more hydrophilic F68 and F127. To get further insight into the underlying drug dissolution mechanisms, critical micellization temperature (CMT), and hydrodynamic size of micelles with and without drug incorporation were determined by UV-visible spectroscopy and dynamic light scattering (DLS) respectively. The micelle-water partition coefficient (P) and location of solubilized drug were also evaluated from a thermodynamics viewpoint. Finally, the optimized media were examined for the release of SRL from drug eluting stent; the data suggest that a release medium consisting of 0.1% P123 in phosphate buffer pH 4.0 is most suitable for evaluation of in-vitro release of SRL from DES.
了解药物洗脱器械(如心脏支架)中药物的体外释放情况对于设计和优化药物嵌入基质至关重要。西罗莫司(SRL)是一种广泛使用的抗炎/抗增殖/免疫抑制性疏水性药物,会发生不可逆的水解等变化,从而导致对释放情况的错误评估。释放情况主要取决于药物释放介质。本研究旨在开发和优化用于溶解 SRL 的水性介质以及从药物洗脱支架(DES)中进行体外释放的方法。在研究的第一阶段,研究人员考察了几种含有不同缓冲组成、pH 值和一系列胶束形成的聚氧化乙烯-聚氧化丙烯-聚氧化乙烯嵌段共聚物(称为 Pluronic(®))的释放介质,以通过反相高效液相色谱法(RP-HPLC)评估 SRL 的溶解度和稳定性。在存在嵌段共聚物的情况下,SRL 在 pH 4.0(醋酸盐缓冲液和磷酸盐缓冲液中均如此)下具有良好的溶解度和稳定性。SRL 在 P103 和 P123 胶束中的溶解度明显高于更亲水的 F68 和 F127。为了更深入地了解药物溶解机制,通过紫外-可见分光光度法和动态光散射(DLS)分别测定了临界胶束化温度(CMT)和药物掺入前后胶束的水动力粒径。还从热力学角度评估了胶束-水分配系数(P)和溶解药物的位置。最后,考察了优化后的介质用于从药物洗脱支架中释放 SRL;数据表明,包含 0.1% P123 的磷酸盐缓冲液 pH 4.0 的释放介质最适合用于评估 DES 中 SRL 的体外释放情况。